Notice2026-18954
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 16, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 178 (Wednesday, September 16, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 178 (Wednesday, September 16, 2026)]
[Notices]
[Page 58689]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-18954]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases
(NIAID), an institute of the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is giving notice of the
invention listed below, which is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing
opportunity should be directed to: Dawn Taylor-Mulneix, or <a href="/cdn-cgi/l/email-protection#e48085938aca90859d888b96c98991888a818d9ca48a8d8cca838b92"><span class="__cf_email__" data-cfemail="83e7e2f4edadf7e2faefecf1aeeef6efede6eafbc3edeaebade4ecf5">[email protected]</span></a>. Licensing information may be obtained by communicating
with the Technology Transfer and Intellectual Property Office, National
Institute of Allergy and Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852: tel. 301-496-2644. A signed Confidential
Disclosure Agreement will be required to receive copies of unpublished
information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Respiratory Syncytial Virus (RSV) G and F Specific Antibodies With High
RSV-Neutralizing Potency
Description of Technology
RSV is a major cause of serious respiratory illness, particularly
in infants, older adults, and people with weakened immune systems. The
virus uses the attachment protein G to bind to host cells and the
fusion protein F to enter them. Although approved RSV antibody products
target F, no licensed antibody currently targets G.
Researchers in NIAID's Laboratory of Infectious Diseases (LID)
developed a monoclonal antibody that targets a conserved region of G
that may be less likely to change over time. In laboratory tests, the
IgG3 subclass of this antibody showed about 9-fold greater neutralizing
activity than licensed RSV antibodies. Researchers also created an IgG1
version to see whether the IgG3 subclass contributed to this strong
activity. The IgG1 version was slightly less potent than the IgG3 form
but still showed strong neutralizing activity. These results suggest
that IgG subclass can influence the neutralizing activity of this G-
targeting antibody.
This technology could support development of first-in-class
antibodies targeting RSV G for the prevention or treatment of RSV
disease, including in people at high risk for severe illness. These G-
targeting antibodies may also be used in combination with existing F-
targeting antibodies to broaden protection and potentially improve
efficacy. Ongoing engineering efforts are aimed at improving the
stability of the G-targeting antibodies and extending their persistence
in the body.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Antibody-based RSV products targeting the attachment
protein G that may be used alone or in combination with existing RSV F-
targeting antibodies to broaden protection.
<bullet> Potential first-in-class antibodies against the RSV G
protein for preventing or treating severe disease.
Competitive Advantages
<bullet> Target the RSV attachment protein G, for which no licensed
antibodies currently exist.
<bullet> Bind a conserved region of the G protein that may be less
likely to change over time, which could help these antibodies remain
effective as the virus evolves.
<bullet> IgG3 G-targeting antibody achieves about 9-fold greater
neutralizing activity in laboratory tests than currently existing
products.
Development Stage
<bullet> Pre-Clinical
Inventors: Dr. Ursula Buchholz, Dr. Cyril Le Nouen, and Dr. Laura
Ahlers, all of NIAID.
Intellectual Property: HHS Reference No. E-117-2024-0. Provisional
Patent Application No. 63/566,064, filed on March 15, 2024, and PCT
Patent Application No. PCT/US2025/020070, filed on March 14, 2025.
Licensing Contact: To license this technology, please contact Dawn
Taylor-Mulneix at 301-451-8021, or <a href="/cdn-cgi/l/email-protection#8befeafce5a5ffeaf2e7e4f9a6e6fee7e5eee2f3cbe5e2e3a5ece4fd"><span class="__cf_email__" data-cfemail="b3d7d2c4dd9dc7d2cadfdcc19edec6dfddd6dacbf3dddadb9dd4dcc5">[email protected]</span></a>, and
reference E-117-2024-0.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Dawn Taylor-Mulneix at 301-451-8021, or
<a href="/cdn-cgi/l/email-protection#284c495f46065c495144475a05455d44464d415068464140064f475e"><span class="__cf_email__" data-cfemail="1b7f7a6c75356f7a6277746936766e77757e72635b757273357c746d">[email protected]</span></a>.
Dated: September 11, 2026.
Surekha Vathyam,
Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2026-18954 Filed 9-15-26; 8:45 am]
BILLING CODE 4167-05-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 16, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.